New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
09:10 EDTZLC, SM, MFRM, UCTT, SUNE, SCTY, DVN, GRMN, CG, ACT, CHTP, TS, X, SIG, OCROn The Fly: Pre-market Movers
UP AFTER EARNINGS: Garmin (GRMN), up 12%... Carlyle Group (CG), up 6.5%... Ultra Clean (UCTT), up 18%... SunEdison (SUNE), up 3%. ALSO HIGHER: Zales (ZLC), up 40% after Signet Jewelers (SIG) to acquire the company for $21.00 per share cash. Signet Jewelers is up 11.6% after the news... Chelsea Therapeutics (CHTP), up 33.5% after Northera granted FDA accelerated approval... Actavis (ACT), up 1.4% after reiterating standalone FY14 adjusted EPS view, shares upgraded at Goldman... Devon Energy (DVN), up 1.8% after earnings, announcing sale of Canadian conventional assets to Canadian Natural Resources (CNQ). DOWN AFTER EARNINGS: Mattress Firm (MFRM), down 10%... Omnicare (OCR), down 4.3%. ALSO LOWER: U.S. Steel (X), down 4.4%, Tenaris down 5.4% after U.S. excludes South Korea from steel tubing tariffs... SolarCity (SCTY), down 1.4% following downgrade at RW Baird... SM Energy (SM), down 11% after earnings, downgrades at Tudor Pickering and KeyBanc.
News For ZLC;SIG;X;TS;CHTP;ACT;CG;GRMN;DVN;SCTY;SUNE;UCTT;MFRM;SM;OCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 15, 2014
07:00 EDTTSTenaris initiated with a Hold at ISI Group
Subscribe for More Information
October 14, 2014
12:55 EDTSIGSignet Jewelers pullback a buying opportunity, says Stephens
Subscribe for More Information
10:01 EDTSMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AU Optronics (AUO) upgraded to Neutral from Sell at UBS... Antero Resources (AR) upgraded to Buy from Accumulate at KLR Group... BHP Billiton (BHP) upgraded to Neutral from Underperform at Credit Suisse... Bill Barrett (BBG) upgraded to Buy from Accumulate at KLR Group... BorgWarner (BWA) upgraded to Buy from Neutral at Goldman... CRH Plc. (CRH) upgraded to Buy from Neutral at Citigroup... Comstock Resources (CRK) upgraded to Buy from Accumulate at KLR Group... Cracker Barrel (CBRL) upgraded at Argus... Delphi Automotive (DLPH) upgraded to Buy from Neutral at Goldman... EOG Resources (EOG) upgraded at Bernstein... Eaton (ETN) upgraded to Overweight from Equal Weight at Barclays... Energizer (ENR) upgraded to Outperform from Market Perform at Wells Fargo... Energy Transfer Equity (ETE) upgraded to Outperform at RW Baird... Federal-Mogul (FDML) upgraded to Neutral from Sell at Goldman... Ford (F) upgraded to Neutral from Underperform at Buckingham... Gulfport Energy (GPOR) upgraded to Accumulate from Hold at KLR Group... Halcon Resources (HK) upgraded to Buy from Hold at KLR Group... HeartWare (HTWR) upgraded to Overweight from Neutral at Piper Jaffray... Helmerich & Payne (HP) upgraded to Outperform at FBR Capital... Legg Mason (LM) upgraded to Neutral from Underperform at BofA/Merrill... Level 3 (LVLT) upgraded to Buy from Hold at Gabelli... Magnum Hunter (MHR) upgraded to Buy from Hold at KLR Group... NetScout (NTCT) upgraded at DA Davidson... Netflix (NFLX) upgraded to Buy with $600 target at BTIG... Newfield Exploration (NFX) upgraded to Buy from Hold at KLR Group... Nielsen (NLSN) upgraded at Bernstein... Orbitz (OWW) upgraded to Outperform from Market Perform at FBR Capital... PDC Energy (PDCE) upgraded to Buy from Hold at KLR Group... Rackspace (RAX) upgraded to Buy from Hold at Evercore... Range Resources (RRC) upgraded to Accumulate from Hold at KLR Group... Rex Energy (REXX) upgraded to Buy from Accumulate at KLR Group... SM Energy (SM) upgraded to Buy from Accumulate at KLR Group... Sanchez Energy (SN) upgraded to Buy from Accumulate at KLR Group... Targa Resources (TRGP) upgraded to Buy from Accumulate at Tudor Pickering... Unilife (UNIS) upgraded to Buy from Neutral at Ladenburg... Universal Forest (UFPI) upgraded at Sterne Agee.
08:40 EDTSMSM Energy upgraded to Buy from Accumulate at KLR Group
Subscribe for More Information
08:04 EDTSIGSignet Jewelers reaffirms Q2 guidance
Subscribe for More Information
08:03 EDTSIGSignet Jewelers CEO Barnes resigns effective October 31, COO Light to succeed
Subscribe for More Information
07:46 EDTACTActavis should be able to mitigate Irish tax downside, says Leerink
Subscribe for More Information
07:37 EDTSUNESunEdison announces zero white space solar module technology
Subscribe for More Information
06:03 EDTACTMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
15:12 EDTACTActavis may see modest negative impact from Irish tax change, says BMO Capital
Subscribe for More Information
10:58 EDTSCTYSolarCity volatility elevated on wide price movement
Subscribe for More Information
08:03 EDTSCTYSolarCity lowered pricing in California, says JPMorgan
JPMorgan says SolarCity lowered its pricing in California, implementing a fixed price of 15c per watt, down from a prior average of 17c. To reflect the change, SolarCity dropped the NPV of its average new residential deployment to $1.75 per watt from $2.19 historically, the firm notes. JPMorgan cut its Retained Value estimates and dropped its price target for SolarCity shares to $74 from $83. The firm believes the price change could be tied to the proposed compression of rate tiers in 2015, allowing the company to address a larger market. It keeps an Overweight rating on SolarCity.
October 10, 2014
10:20 EDTACTFidelity supports potential merger between Actavis and Allergan, Reuters reports
Subscribe for More Information
07:37 EDTACTActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
October 9, 2014
18:02 EDTSMSM Energy sees Q3 production at lower end of previous guidance range
Subscribe for More Information
12:28 EDTACTAllergan price target raised to $230 from $210 at BTIG
BTIG said it expected Allergan to beat the consensus forecast for Q3 EPS, but not by as much as it did, and the firm did not expect the company to raise its future EPS outlook yet again. BTIG feels the stock's move higher indicates Valeant (VRX) or Actavis (ACT) would need to bid above $200 if they hope to buy the company. BTIG maintains its Buy rating on Allergan and raised its price target on the stock to $230 from $210.
11:14 EDTACTAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
08:53 EDTSCTYSolarCity solar loans could be a game changer, says Roth Capital
Subscribe for More Information
08:50 EDTACTAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
07:08 EDTXCanadian court approves U.S. Steel division DIP financing, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use